Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions

Parkinson's Disease (PD)

Interventions

DRUG

EC5026 oral tablet

Oral soluble epoxide hydrolase inhibitor

DRUG

Placebo

Matching oral placebo

Trial Locations (1)

RECRUITING

University of California Davis, Sacramento

All Listed Sponsors

collaborator

University of California, Davis

OTHER

collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

EicOsis Human Health Inc.

INDUSTRY

NCT07142044 - Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study) | Biotech Hunter | Biotech Hunter